Phase II Crossover Trial of Varenicline in Mild-to-Moderate Alzheimer's Disease.

Conclusions: Varenicline did not improve cognition, behavior or global change in this population. The most frequent varenicline-associated AEs were gastrointestinal; psychiatric AEs were rare and similar between the groups. © 2013 S. Karger AG, Basel. PMID: 24247022 [PubMed - as supplied by publisher]
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research